Cyclic peptides open new drug frontiers, if manufacturing can keep up

Summary

Cyclic peptides are emerging as a promising drug modality combining small molecule convenience with antibody-like selectivity, though manufacturing challenges and low bioavailability remain obstacles. Viva Biotech outlined approaches using hybrid synthesis, ADME/PK modeling, and AI-guided design to advance cyclic peptide therapeutics.